Inactive Instrument

Cubist Pharmaceuticals Inc Share Price

Equities

End-of-day quote Nasdaq Other stock markets
- ^USD	-

2014	Cubist Pharmaceuticals : sales force seen as potential boon for Merck intestinal drug	RE
2014	Cubist Pharmaceuticals : Merck says still plans to buy Cubist, despite patent setback	RE

Cubist Pharmaceuticals : sales force seen as potential boon for Merck intestinal drug	10/14/10	RE
Cubist Pharmaceuticals : Merck says still plans to buy Cubist, despite patent setback	09/14/09	RE
Merck : to take on superbugs with Cubist Pharma buy	09/14/09	RE
AstraZeneca : Merck to take on superbugs with Cubist Pharma buy	09/14/09	RE
Apple : S&P 500 posts worst day since Oct; energy shares sink	09/14/09	RE
Cubist Pharmaceuticals : options unusually active before Merck deal	08/14/08	RE
Cubist Pharmaceuticals : Merck in talks to acquire Cubist Pharmaceuticals for more than $7 billion - NYT	06/14/06	RE
Cubist Pharmaceuticals Inc : U.S. court ruling favors Cubist in patent case versus Hospira	21/13/21	RE

Cubist Pharmaceuticals : Announces Withdrawal of Listing of CVRs (CBSTZ) from NASDAQ Global Select Market	13/15/13	BU
Cubist Pharmaceuticals : Announces FDA Approval of New Antibiotic ZERBAXA™ (Ceftolozane/Tazobactam) for Complicated Urinary Tract and Complicated Intra-abdominal Infections	20/14/20	BU
Cubist Pharmaceuticals : Ryan & Maniskas, LLP : Announces Investigation of Cubist Pharmaceuticals Inc.	09/14/09	PR
Cubist Pharmaceuticals : Comments on CUBICIN Patent Litigation	09/14/09	BU
Cubist Pharmaceuticals : European Antibiotic Awareness Day Highlights Need for Urgent Action	17/14/17	PU

Cubist Pharmaceuticals : meldet FDA-Zulassung seines neuen Antibiotikums ZERBAXA™ (Ceftolozan/Tazobactam) für komplizierte Harnwegsinfektionen und komplizierte intraabdominelle Infektionen	21/14/21
Cubist Pharmaceuticals : annonce l’approbation par la FDA du nouvel antibiotique ZERBAXA™ (ceftolozane/tazobactam) pour le traitement des infections urinaires compliquées et des infections intra-abdominales compliquées	21/14/21
Cubist Pharmaceuticals : Merck & Co acquiert Cubist Pharma pour 8,4 milliards de dollars	08/14/08
Cubist Pharmaceuticals : Wall Street ouvre en baisse, l'Asie inquiète	08/14/08
Isetan Mitsukoshi : Les valeurs à suivre sur les marchés américains	08/14/08

Managers	Title	Age	Since
Karen Rogers PRN	Corporate Officer/Principal	-	-
Phyllis Rae Abbuhl SAM	Sales & Marketing	-	-
Frederick B. Oleson PRN	Corporate Officer/Principal	-	01/97/01

Members of the board	Title	Age	Since
Martin Hermanus Soeters BRD	Director/Board Member	70	01/06/01
Kenneth J. Martin BRD	Director/Board Member	70	25/13/25

Sector

	1st Jan change	Capi.
SAMSUNG BIOLOGICS CO.,LTD.	+1.45%	40.51B
BIOGEN INC.	-15.94%	31.67B
UCB	+52.66%	24.62B
BIOMARIN PHARMACEUTICAL INC.	-14.50%	15.65B
INCYTE CORPORATION	-14.38%	12.07B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.12%	11.97B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-42.56%	11.61B
SWEDISH ORPHAN BIOVITRUM AB	+4.87%	8.81B
INNOVENT BIOLOGICS, INC.	-4.33%	8.5B